Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Dexcom (DXCM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PolyPid (PYPD – Research Report), Dexcom (DXCM – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PolyPid (PYPD)
Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on PolyPid today and set a price target of $9.00. The company’s shares closed last Thursday at $4.59.
According to TipRanks.com, Pachaiyappan is a 4-star analyst with an average return of
PolyPid has an analyst consensus of Strong Buy, with a price target consensus of $11.67, a 153.7% upside from current levels. In a report issued on February 9, Craig-Hallum also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Dexcom (DXCM)
Citi analyst Joanne Wuensch maintained a Buy rating on Dexcom today. The company’s shares closed last Friday at $66.33, close to its 52-week low of $62.34.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $86.69 average price target, a 27.2% upside from current levels. In a report issued on January 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $85.00 price target.
BridgeBio Pharma (BBIO)
Wells Fargo analyst Derek Archila reiterated a Buy rating on BridgeBio Pharma today and set a price target of $98.00. The company’s shares closed last Friday at $76.47.
According to TipRanks.com, Archila is a 5-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $100.14, representing a 36.6% upside. In a report issued on January 29, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.
